Violations at Novo’s Indiana Plant ‘Unacceptable,’ FDA Says

Slapped with the most severe post-inspection classification, the state of Novo Nordisk’s Indiana manufacturing site could pose a problem for clients, including Regeneron and Scholar Rock.